Skip to main content
Premium Trial:

Request an Annual Quote

Phenomenex Spins Off New Firm Neoteryx Focused on Sample Collection

Premium

NEW YORK (GenomeWeb) – Phenomenex said this week that it is spinning off a new biological samples company, Neoteryx, focused on providing microsampling products that enable simpler, less invasive, and cost-effective methods of collecting and testing biological samples.

The new firm's main technology is its Volumetric Absorptive Microsampling (VAMS) technology. According to the company, the first product based on this technology – the Mitra Microsample Device – can collect 10 µL of fluid in seconds without volumetric blood hematocrit bias.

The company is aiming the product at areas including pharmaceutical development, personalized medicine, clinical research, and clinical diagnostics.

It will compete with a similar device launched this year by Novilytic Laboratories. That company's device, its Noviplex Cards, similarly serves as an alternative to traditional blood draws, processing finger stick blood samples and take it through sample prep and hematocrit standardization on the card.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.